Shares of Aurobindo Pharma Ltd have been buying and selling virtually 1% decrease on Monday, 8 September, after the corporate obtained eight observations from the US Meals and Drug Administration (USFDA).
The USFDA visited the corporate’s Unit-XII, which incorporates oral solids and injectable manufacturing, in Bachupally, Medchal Malkajgiri District, Telangana, from 25 August to five September 2025.
On the conclusion of the current inspection, a ‘Kind 483’ was issued with a complete of 8 observations for each (oral solids and injectable).
All observations are procedural in nature, and the corporate said that it’ll react to the US FDA inside the timeframe specified.
Earlier, on 29 August, the USFDA issued a Kind 483 with 5 remarks after visiting Unit-I, an API manufacturing facility of the corporate’s affiliate Apitoria Pharma in Sangareddy, Telangana, from 21 August to 29 August.
The observations have been procedural in nature, and no information integrity considerations have been raised.
At 1:16 pm, the shares of Aurobindo Pharma have been buying and selling 0.12% increased at Rs 1,045.40 on NSE.
Uncover the subsequent huge funding! Unicorn Indicators’ IPO screener helps you establish promising preliminary public choices. Obtain Unicorn Indicators and get forward of the curve! Signal Up Now & Discover Your Subsequent IPO Gem!
